Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry
– Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD
– Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo
– Safety analysis showed adverse event profile comparable to placebo, with no signs or symptoms of withdrawal or psychotomimetic effects associated with NMDAR blocking
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases
ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers
Clinical trials for ImmunoGenesis drug candidates to initiate in 2022
Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
AllianceChicago to Offer Wellsheet’s Predictive Clinical Workflow Platform Integrated with athenahealth’s EHR
Wellsheet Integration with athenaOne to Empower Primary Care Clinicians in Community Health Centers
Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
– IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern
– IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well as natural viral clearance mechanisms
Immunome Reports Third Quarter 2021 Financial Results
– IMM-BCP-01 Progressing Towards IND Filing –
Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing
Released topline preclinical data demonstrating feasibility of REN-001 to transduce a large animal heart via local infusion at low vector doses
Strengthened company leadership with key appointments including Matthew Killeen, Ph.D., as CSO, and Elizabeth White, Ph.D., as CBO and SVP of Operations